Evidence map›Paper›PMID 28944862›Full record

ArticleMolecular medicine reports2017

ING2, a tumor associated gene, enhances PAI‑1 and HSPA1A expression with HDAC1 and mSin3A through the PHD domain and C‑terminal.

Chiyo Ohkouchi, Kensuke Kumamoto, Motonobu Saito, Teruhide Ishigame, Shin-Ichi Suzuki, Seiichi Takenoshita, Cutis C Harris

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Gal-2 Increases H3K4meBiomolecules · 2022
    Article
  4. WhyWorld journal of clinical cases · 2021
    Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Chiyo OhkouchiDepartment of Thyroid and Endocrinology, Fukushima Medical University School of Medicine, Fukushima 960‑1295, Japan.
Kensuke KumamotoDepartment of Coloproctology, Aizu Medical Center, Fukushima Medical University, Aizuwakamatsu, Fukushima 969‑3492, Japan.
Motonobu SaitoLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Teruhide IshigameLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Shin-Ichi SuzukiDepartment of Thyroid and Endocrinology, Fukushima Medical University School of Medicine, Fukushima 960‑1295, Japan.
Seiichi TakenoshitaDepartment of Organ Regulatory Surgery, Fukushima Medical University School of Medicine, Fukushima 960‑1295, Japan.
Cutis C HarrisLaboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Fukushima Medical University · JPCenter for Cancer Research · USNational Cancer Institute · USNational Institutes of Health · US

Funding

p53, Aging, and CancerZIABC011496 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HARRIS, CURTIS · 2013 to 2025
$21.1M
6 · The paper itself

Abstract

Inhibitor of growth 2 (ING2) is involved in chromatin remodeling and it has previously been suggested that ING2 may regulate gene expression. The authors previously identified matrix metalloproteinase 13 (MMP13) as a target gene of ING2 in colorectal cancer. The aim of the present study was to identify novel genes regulated by ING2 and histone deacetylase 1 (HDAC1) and to clarify the biological significance of the ING2 structure. The present study generated the point mutant constructs of ING2 and deletion constructs consisting of partial ING2 to investigate the effect on gene expression and verify the interaction with HDAC1, mSin3A and sap30. A microarray was performed to find novel ING2/HDAC1 target genes using cell co‑overexpression of ING2 and HDAC1. Plasminogen activator inhibitor‑1 (PAI‑1) was upregulated with overexpression of ING1b and ING2. The mutation of the PHD domain at 218 significantly attenuated the MMP13 and PAI‑1 expression, whereas the mutation at 224 resulted in increased expression. Furthermore, the expression levels were slightly reduced by the mutation of the C‑terminal. The lack of the PHD domain and the C‑terminal in ING2 resulted in a decreased ability to induce gene expression. The C‑terminal with PHD domain, which lacked the N‑terminal, maintained the transactive function for regulating the target genes. In addition to MMP13 and PAI‑1, eight genes [heat shock protein family A member 1A (HSPA1A), MIR7‑3 host gene, chorionic somatomammotropin hormone 1, growth arrest and DNA damage inducible b, dehydrogenase/reductase 2, galectin 1, myosin light chain 1, and VGF nerve growth factor inducible] were demonstrated to be associated with ING2/HDAC1. The present study demonstrated that ING2/HDAC1 regulated PAI‑1 and HSPA1A expression and the PHD domain and the C‑terminal of ING2, which are binding sites of HDAC1 and mSin3A, are essential regions for the regulation of gene expression.

Indexed as

HEK293 CellsHistone Deacetylase 1Histone DeacetylasesHomeodomain ProteinsHSP70 Heat-Shock ProteinsHumansInhibitor of Growth Protein 1Matrix Metalloproteinase 13Matrix Metalloproteinase 2PHD Zinc FingersPlasmidsPlasminogen Activator Inhibitor 1Point MutationProtein Array AnalysisReceptors, Cytoplasmic and NuclearRepressor ProteinsHDAC1 protein, humanHistone Deacetylase 1Histone DeacetylasesHomeodomain ProteinsHSP70 Heat-Shock ProteinsHSPA1A protein, humanING2 protein, humanInhibitor of Growth Protein 1Matrix Metalloproteinase 13Matrix Metalloproteinase 2Plasminogen Activator Inhibitor 1Receptors, Cytoplasmic and NuclearRepressor ProteinsSAP30 protein, humanSIN3A transcription factorSin3 Histone Deacetylase and Corepressor ComplexTumor Suppressor Proteins

Identifiers

PMID28944862
PMCPMC5865867
OpenAlexW2754972463

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.